Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.

about

[Caspase-1 regulates autoinflammation in rheumatic diseases].Tocilizumab (Actemra).

P2860

Q34520488-F5A3C760-2EC7-4229-8F19-FBD9F03578B6 Q47978774-4414AE2D-E501-4697-B260-6DC64A913133

P2860

Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.

Item

http://www.wikidata.org/entity/Q38176004

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Treatment of Systemic Juvenile ...... y After a Decade of Treatment.

@en

type

Item

label

Treatment of Systemic Juvenile ...... y After a Decade of Treatment.

@en

prefLabel

Treatment of Systemic Juvenile ...... y After a Decade of Treatment.

@en

P1476

Treatment of Systemic Juvenile ...... y After a Decade of Treatment.

@en

P2093

Andreas Reiff

http://www.w3.org/2001/XMLSchema#string

P2860

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolong

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Medical treatment of juvenile idiopathic arthritis.

Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

P2888

s13554-012-0001-6

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13554-012-0001-6

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257804917

http://www.w3.org/2001/XMLSchema#string

P6179

1044487705

http://www.w3.org/2001/XMLSchema#string

P698

24392296

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

P932

3873121

http://www.w3.org/2001/XMLSchema#string

Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.

about

P2860

P2860

Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P921

P932